LEADER 01096nam--2200397---450-
001 990001336530203316
005 20040108103703.0
035   $a000133653
035   $aUSA01000133653
035   $a(ALEPH)000133653USA01
035   $a000133653
100   $a20040108d1976----km-y0itay0103----ba
101 0 $aita
102   $aIT
105   $a||||||||001yy
200 1 $aCapitalismo ed economia$fGiulio Pietranera
205   $a3
210   $aTorino$cG. Einaudi$d1976
215   $a245 p$d18 cm
225 2 $aPiccola biblioteca Einaudi$v84
410  0$12001$aPiccola biblioteca Einaudi$v84
454  1$12001
461  1$1001-------$12001
606 0 $aCapitalismo
606 0 $aEconomia socialista
676   $a330.122
700  1$aPIETRANERA,$bGiulio$0119656
801  0$aIT$bsalbc$gISBD
912   $a990001336530203316
951   $aVarie Coll. 11/84$b119651 L.M.$cVarie Coll.
959   $aBK
969   $aUMA
979   $aSIAV2$b10$c20040108$lUSA01$h1037
979   $aPATRY$b90$c20040406$lUSA01$h1735
996   $aCapitalismo ed economia$9201559
997   $aUNISA

LEADER 03485nam  2200589Ia 450 
001 9910451510103321
005 20190321174301.0
010   $a1-280-24804-1
035   $a(CKB)1000000000450557
035   $a(EBL)3377603
035   $a(SSID)ssj0000119076
035   $a(PQKBManifestationID)11145624
035   $a(PQKBTitleCode)TC0000119076
035   $a(PQKBWorkID)10057857
035   $a(PQKB)11612462
035   $a(OCoLC)229431501
035   $a(MiAaPQ)EBC3377603
035   $a(EXLCZ)991000000000450557
100   $a20020131d2001      uy             0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 00$aCDC anthrax vaccine safety & efficacy research program $einterim report$b[electronic resource] /$fInstitute of Medicine
210   $aWashington, D.C. $cNational Academy Press$dc2001
215   $a1 online resource (57 p.)
300   $a"Prepublication copy; uncorrected proofs".
311   $a9786610248049 
311   $a0-309-57987-2 
320   $aIncludes bibliographical references.
327   $a""CDC Anthrax Vaccine Safety & Efficacy Research Program""; ""Copyright""; ""Contents""; ""Preface""; ""Acknowledgments""; ""REVIEWERS""; ""Executive Summary""; ""PROJECT-SPECIFIC FINDINGS AND RECOMMENDATIONS""; ""NCID-Directed Projects in the Research Program""; ""Human Clinical Trial, or Part A""; ""Animal dose ranging and challenge studies, or Part B""; ""Assays addressing correlates of immunity, or Part C""; ""Human Leukocyte Antigen (HLA) substudy""; ""NIP-Directed Projects of the Research Program""
327   $a""Survey of knowledge, attitudes, and beliefs of military personnel about the anthrax vaccine""""Survey of knowledge, attitudes, and beliefs of military vaccinee providers about VAERS reporting""; ""CDC proposal for use of the Short Form 36""; ""Remaining components of the research program directed by the NIP""; ""1 Introduction and Background ""; ""ANTHRAX DISEASE AND PREVENTION""; ""Anthrax Disease""; ""Anthrax Vaccine""; ""VACCINE RELATED ADVERSE EVENTS""; ""POLICY CONTEXT OF REPORT""; ""Anthrax Vaccination Policy""; ""CDC'S RESPONSE TO CONGRESS""
327   $a""2 Interim Findings and Recommendations """"NCID RESEARCH ACTIVITIES""; ""Part A: Clinical Trial""; ""CDC proposal for use of the Short Form 36""; ""Part B: Non-human Primate Dose-Ranging and Challenge Study""; ""Part C: Assays of Immunologic Correlates of Protection""; ""NIP RESEARCH ACTIVITIES""; ""Knowledge, Attitudes, and Beliefs of Military Personnel about the Anthrax Vaccine""; ""Knowledge, Attitudes, and Beliefs of Vaccine Providers about VAERS Reporting""; ""Data Mining Using the VAERS Database""; ""Meta-Analysis of Existing Studies on the Anthrax Vaccine""; ""REFERENCES""
327   $a""ACRONYMS""""Appendix A Study Activities ""; ""Appendix B Biographical Sketches ""
606   $aAnthrax$xVaccination
606   $aVaccines$xEffectiveness
606   $aVaccines$xSafety measures
608   $aElectronic books.
615  0$aAnthrax$xVaccination.
615  0$aVaccines$xEffectiveness.
615  0$aVaccines$xSafety measures.
676   $a616.956
712 02$aInstitute of Medicine (U.S.)
712 02$aCommunicable Disease Center (U.S.)
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910451510103321
996   $aCDC anthrax vaccine safety & efficacy research program$91977537
997   $aUNINA